Learn how LABD delivers -3x daily biotech exposure, why it’s down 99.98% since inception, and when it fits short-term trades.

Shares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full analysis here.

Shares of Moderna (MRNA) have surged sharply this week, drawing renewed attention to exchange traded funds with significant ...

Our senior market strategist explains which ETFs offer exposure to high-powered biotech growth, without T. Rex-sized risk.

Shares of biotech companies were outpacing the broader market on Thursday. The State Street SPDR S&P Biotech ETF was up 2.7%, compared with the 0.8% gain of the S&P 500. A significant portion of these ...

For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and has risen 98.15% from its 52-week low price of $66.66/share. But ...

On the buying side, ARK continues to show interest in the artificial intelligence space. The fund acquired 7,737 shares of Tempus AI Inc (NASDAQ:TEM) across its ARKK and ARKG ETFs, totaling $505,380.

ARK Invest bought $7.27M Netflix stock and sold $4.19M Beam Therapeutics on Jan 21, 2026. Full breakdown of Cathie Wood's ...

ARK Invest sold $5M Beam Therapeutics and bought WeRide, Tempus AI stock Jan 22. See Cathie Wood's complete trading report and portfolio changes.

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, ...